Innovative, Minimally Invasive Treatment for Drug-Resistant Epilepsy

Epilepsy remains a life-altering condition, particularly due to the unpredictable nature of seizures and their cumulative impact on cognition, independence and quality of life. Despite continued advances in antiseizure medications, approximately one-third of people with epilepsy meet criteria for drug-resistant epilepsy, defined as failure of two appropriately selected and tolerated medications. For these patients, surgical intervention offers the highest likelihood of seizure freedom when guided by precise localization and comprehensive multidisciplinary evaluation.

Phoenix Children’s, recently cared for a 19-year-old woman with drug-resistant epilepsy associated with bilateral periventricular nodular heterotopia (PVNH) due to a pathogenic FLNA mutation – a population well recognized for complex, often multifocal epileptogenic networks.

Her presurgical evaluation highlighted the challenges of network-level epilepsy, with notably discordant data:

• Seizure semiology suggesting a right parietal onset
• Scalp EEG indicating a right central focus
• FDG-PET demonstrating left anterior temporal hypometabolism
• Magnetoencephalography (MEG) suggesting left frontal involvement

This lack of convergence precluded a straightforward resective approach. Meanwhile, her persistent weekly seizures were significantly impairing her ability to pursue higher education and limiting long-term independence.

Given this complexity, she underwent stereo-electroencephalography (sEEG) implantation with 10 bilateral depth electrodes to better define the epileptogenic zone. sEEG revealed spontaneous electroclinical seizures originating from a discrete focus within one of the heterotopic nodules.

Rather than proceeding with open resection, a targeted, minimally invasive approach was employed: radiofrequency thermocoagulation (RF-TC) delivered through the implanted depth electrodes. Although RF-TC is an established and clinically validated technique, its adoption remains limited across many epilepsy centers. This underutilization appears to stem not only from variable levels of awareness, but also from hesitancy to incorporate newer technologies and procedural approaches into established clinical workflows. Such reluctance may be particularly pronounced in the context of complex and multifocal epilepsies, including PVNH, where treatment paradigms are less standardized and outcomes can be more difficult to predict. In this case, selected electrode contacts were ablated at the bedside while the patient was awake, requiring only minutes to perform and avoiding the risks associated with open surgery. Following the intervention, her previously weekly seizures have resolved, representing a marked and clinically meaningful improvement in seizure control. This sustained seizure freedom has had a significant impact on her day-to-day functioning and overall quality of life. She is now considering resuming her college education and pursuing a more independent lifestyle.

Broader Implications for Epilepsy Care

Her clinical course underscores several critical principles in contemporary epilepsy care. While antiseizure medications are effective for most patients, those who fail appropriate trials require timely escalation. Early referral to a Level 4 epilepsy center ensures access to advanced diagnostics and the full spectrum of therapeutic options for complex epilepsy.

Optimal outcomes in drug-resistant epilepsy depend on a truly multidisciplinary approach. Close collaboration among epileptologists, epilepsy neurosurgeons, neuroradiologists, neuropsychologists and specialized care teams allows for individualized, data-driven treatment strategies, particularly in cases with discordant findings or distributed epileptic networks.

At the same time, the rapid evolution of epilepsy technologies continues to expand what is possible. Advances in intracranial monitoring, imaging and minimally invasive therapies are enabling increasingly precise localization and targeted intervention. Techniques such as sEEG-guided RF-TC, laser interstitial thermal therapy (LITT) and neuromodulation strategies are shifting the paradigm toward more tailored, less invasive and more effective treatments. These innovations are best implemented in centers with the expertise and infrastructure to manage highly complex cases.

Over the past decade, the treatment landscape for drug-resistant epilepsy has expanded dramatically. In addition to traditional resective surgery, options now include LITT, responsive neurostimulation (RNS) targeting cortical or thalamic networks, vagus nerve stimulation (VNS) and deep brain stimulation (DBS). These advances have broadened the population of patients considered for intervention, including those with multifocal, bilateral or genetically mediated epilepsies, through staged approaches or palliative strategies aimed at meaningful seizure reduction and improved quality of life.

Reflecting these advances, the American Academy of Neurology has established quality measures emphasizing early referral: patients with persistent seizures despite appropriate medication trials, or those requiring multiple antiseizure medications within a short timeframe, should be evaluated at a comprehensive epilepsy center. Despite this, delayed referral remains a significant barrier to optimal care nationwide.

Patients with complex or drug-resistant epilepsy should be referred early to specialized centers with expertise in advanced diagnostic and therapeutic approaches. Phoenix Children’s Epilepsy Program provides comprehensive evaluation and access to advanced therapeutic options. Referrals can be initiated through Phoenix Children’s Neurology at 602-933-0970 to facilitate timely access to specialized care.

Dr. Williams leads the Pediatric Epilepsy Program at Phoenix Children’s and specializes in the evaluation and management of complex, drug?resistant epilepsies. His clinical and academic interests focus on advanced neurodiagnostics, minimally invasive therapies and improving outcomes for children and young adults with refractory seizure disorders.

Physicians with patients who meet criteria for drug-resistant epilepsy are encouraged to contact the Phoenix Children’s Epilepsy Program for evaluation.